These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 28336827)

  • 1. [Pathophysiology of secondary hyperparathyroidism.].
    Kawarazaki H
    Clin Calcium; 2017; 27(4):515-520. PubMed ID: 28336827
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Current treatment options for secondary hyperparathyroidism in patients with stage 3 to 4 chronic kidney disease and vitamin D deficiency.
    Galassi A; Ciceri P; Porata G; Iatrino R; Boni Brivio G; Fasulo E; Magagnoli L; Stucchi A; Frittoli M; Cara A; Cozzolino M
    Expert Opin Drug Saf; 2021 Nov; 20(11):1333-1349. PubMed ID: 33993809
    [No Abstract]   [Full Text] [Related]  

  • 3. [The pathophysiology of secondary hyperparathyroidism].
    Tokumoto M
    Clin Calcium; 2016 Jun; 26(6):821-9. PubMed ID: 27230837
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cinacalcet HCl: a novel treatment for secondary hyperparathyroidism caused by chronic kidney disease.
    Torres PU
    J Ren Nutr; 2006 Jul; 16(3):253-8. PubMed ID: 16825031
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Management of secondary hyperparathyroidism in uremic patients: the role of the new vitamin D analogs.
    Brancaccio D; Cozzolino M; Galassi A; Chiarelli G; Butti A; Bellasi A; Rocca-Rey L; Volpi A; Anelli A; Zoni U; Fusaro M; Brambilla C; Missaglia E; Crovetto C; Russo M; Longhini C; Provenzano R; Incalcaterra F; Cerasola G; Li Vecchi M; Gallieni M
    J Nephrol; 2007; 20(1):3-9. PubMed ID: 17347966
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Calcium-sensing receptor, calcimimetics, and cardiovascular calcifications in chronic kidney disease.
    Torres PA; De Broe M
    Kidney Int; 2012 Jul; 82(1):19-25. PubMed ID: 22437409
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment Failure of Active Vitamin D Therapy in Chronic Kidney Disease: Predictive Factors.
    Cozzolino M; Covic A; Martinez-Placencia B; Xynos K
    Am J Nephrol; 2015; 42(3):228-36. PubMed ID: 26439891
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vitamin D, vitamin D receptor and the importance of its activation in patients with chronic kidney disease.
    Bover J; Egido J; Fernández-Giráldez E; Praga M; Solozábal-Campos C; Torregrosa JV; Martínez-Castelao A
    Nefrologia; 2015; 35(1):28-41. PubMed ID: 25611831
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Importance of Adherence in the Treatment of Secondary Hyperparathyroidism.
    Alfieri C; Regalia A; Zanoni F; Vettoretti S; Cozzolino M; Messa P
    Blood Purif; 2019; 47(1-3):37-44. PubMed ID: 30223271
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pathophysiology of calcium and phosphate metabolism impairment in chronic kidney disease.
    Cozzolino M; Ciceri P; Volpi EM; Olivi L; Messa PG
    Blood Purif; 2009; 27(4):338-44. PubMed ID: 19295196
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vitamin D in Chronic Kidney Disease and Dialysis Patients.
    Jean G; Souberbielle JC; Chazot C
    Nutrients; 2017 Mar; 9(4):. PubMed ID: 28346348
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Control of secondary hyperparathyroidism by vitamin D receptor agonists in chronic kidney disease.
    Sprague SM; Coyne D
    Clin J Am Soc Nephrol; 2010 Mar; 5(3):512-8. PubMed ID: 20133492
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Pathogenesis of secondary hyperparathyroidism and renal bone disease].
    Ito H; Kinugasa E
    Clin Calcium; 2004 May; 14(5):720-5. PubMed ID: 15577032
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Calcifediol to treat secondary hyperparathyroidism in patients with chronic kidney disease.
    Galassi A; Bellasi A; Ciceri P; Pivari F; Conte F; Cozzolino M
    Expert Rev Clin Pharmacol; 2017 Oct; 10(10):1073-1084. PubMed ID: 28846459
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of vitamin d receptor activators in cardio-renal syndromes.
    Cozzolino M; Bruschetta E; Stucchi A; Ronco C; Cusi D
    Semin Nephrol; 2012 Jan; 32(1):63-9. PubMed ID: 22365164
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Prevalence of secondary hyperparathyroidism (SHPT) and causal factors in adult population in Reykjavík area].
    Karlsson SL; Indridason OS; Franzson L; Sigurdsson G
    Laeknabladid; 2005 Feb; 91(2):161-9. PubMed ID: 16155312
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Secondary hyperparathyroidism in chronic kidney disease: focus on clinical consequences and vitamin D therapies.
    Hudson JQ
    Ann Pharmacother; 2006 Sep; 40(9):1584-93. PubMed ID: 16912241
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New approaches to treatment of secondary hyperparathyroidism.
    Locatelli F; Limardo M; Pontoriero G
    Curr Opin Investig Drugs; 2008 Apr; 9(4):363-70. PubMed ID: 18393103
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vitamin D deficiency and secondary hyperparathyroidism among patients with chronic kidney disease.
    Khan S
    Am J Med Sci; 2007 Apr; 333(4):201-7. PubMed ID: 17435411
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vitamin D supplementation in CKD.
    Martin KJ; González EA
    Clin Nephrol; 2011 Apr; 75(4):286-93. PubMed ID: 21426882
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.